|Bid||115.53 x 100|
|Ask||138.00 x 200|
|Day's Range||132.70 - 137.90|
|52 Week Range||75.52 - 153.15|
|PE Ratio (TTM)||-243.68|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Earnings season kicked off on a positive note for biotech stocks with big players like Amgen (AMGN) and Biogen reporting better than expected results.
Gilead Sciences, Inc.'s revenue is estimated to decline by just over 18% when it reports its Q2 results.
Eli Lilly and Incyte gave an update on rheumatoid arthritis drug baricitinib as Lilly unveiled second-quarter numbers that surpassed analyst estimates.